Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone in pediatric bipolar I disorder (manic or mixed), 4-week placebo-controlled phase 3 trial
2015-000606-20Phase 3
- Sponsor
- Pfizer
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bipolar I disorder comparing Ziprasidone with Placebo (2 arms). Primary endpoint: Change from baseline in Young Mania Rating Scale total score at Week 4.
02
Drugs
ziprasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2015-000606-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000606-20.